Each year, an estimated 3.6 million episodes of RVGE occur among the 23.6 million children under 5 years of age in the European Union.1 Yet early vaccination can provide a high degree of protection for infants before the peak incidence of the disease.
Prof. Dr. Timo Vesikari, University of Tampere, Finland, lead author for the European recommendations commented, “Rotavirus affects almost all young children causing severe diarrhoea and vomiting. In the most severe cases, infants may need to be hospitalised. This causes a considerable burden on hospitals where it can spread rapidly through paediatric wards. We convened a group of experts to address the rotavirus issue and have concluded that to effectively reduce the burden of rotavirus gastroenteritis in Europe, universal vaccination of infants is recommended. The vaccines available are effective, have a good safety profile and can fit in with existing national vaccine schedules.”
“This recommendation for universal vaccination against rotavirus is very good news for European infants, their parents and hospitals,” said Jean Stéphenne, president of GSK Biologicals. “Rotavirus vaccination can provide a high degree of protection against rotavirus disease and its distressing symptoms that many children suffer. Fortunately, not many children die in Europe from rotavirus infection, but the burden on healthcare resources needed in treating outbreaks of the disease is very high and the vaccine will resolve major issues for paediatric hospitals.”
Rotavirus is the primary cause of acute gastroenteritis (diarrhoea and vomiting) leading to hospitalisation of infants and young children. New evidence presented today at the ESPID annual meeting shows that the burden of disease may be even higher than previously described. A study conducted in French, German, Italian, Spanish and UK hospitals investigated the burden of RVGE in children under 5 years of age over a 19-month period.2 The results show that rotavirus accounts for 56.2% of hospitalisations due to acute gastroenteritis. RVGE is more common in younger children, with a majority of cases occurring in children under 2 years and 18% of cases occurring in infants less than 6 months of age.2 Previous studies have reported that the duration of hospitalisation is longest in the youngest infants, particularly those who are under 4 months of age.3
Vaccination is the most effective way to provide a high level of protection for young children against RVGE.4,5 New data announced at the ESPID congress show that Rotarix™ provides sustained protection in children against RVGE up to the age of 2 years.6 Given in a convenient two-dose schedule, the oral vaccine offers early protection, before the peak incidence of the disease at 6-24 months.7 Rotarix™ prevents 96% of hospitalisations due to RVGE and reduces the need for medical attention by 84%.6 Principle investigator, Prof. Dr. Timo Vesikari, commented, “The new data substantiate the evidence for Rotarix™ showing that the vaccine’s efficacy is proven over the first two years of life which is the most vulnerable period to suffer from severe rotavirus gastroenteritis.”
Luke Willats | alfa
Routing gene therapy directly into the brain
07.12.2017 | Boston Children's Hospital
New Hope for Cancer Therapies: Targeted Monitoring may help Improve Tumor Treatment
01.12.2017 | Berliner Institut für Gesundheitsforschung / Berlin Institute of Health (BIH)
MPQ scientists achieve long storage times for photonic quantum bits which break the lower bound for direct teleportation in a global quantum network.
Concerning the development of quantum memories for the realization of global quantum networks, scientists of the Quantum Dynamics Division led by Professor...
Researchers have developed a water cloaking concept based on electromagnetic forces that could eliminate an object's wake, greatly reducing its drag while...
Tiny pores at a cell's entryway act as miniature bouncers, letting in some electrically charged atoms--ions--but blocking others. Operating as exquisitely sensitive filters, these "ion channels" play a critical role in biological functions such as muscle contraction and the firing of brain cells.
To rapidly transport the right ions through the cell membrane, the tiny channels rely on a complex interplay between the ions and surrounding molecules,...
The miniaturization of the current technology of storage media is hindered by fundamental limits of quantum mechanics. A new approach consists in using so-called spin-crossover molecules as the smallest possible storage unit. Similar to normal hard drives, these special molecules can save information via their magnetic state. A research team from Kiel University has now managed to successfully place a new class of spin-crossover molecules onto a surface and to improve the molecule’s storage capacity. The storage density of conventional hard drives could therefore theoretically be increased by more than one hundred fold. The study has been published in the scientific journal Nano Letters.
Over the past few years, the building blocks of storage media have gotten ever smaller. But further miniaturization of the current technology is hindered by...
With innovative experiments, researchers at the Helmholtz-Zentrums Geesthacht and the Technical University Hamburg unravel why tiny metallic structures are extremely strong
Light-weight and simultaneously strong – porous metallic nanomaterials promise interesting applications as, for instance, for future aeroplanes with enhanced...
11.12.2017 | Event News
08.12.2017 | Event News
07.12.2017 | Event News
12.12.2017 | Physics and Astronomy
12.12.2017 | Earth Sciences
12.12.2017 | Power and Electrical Engineering